Mustgrow Biologics Corp Stock Price, News & Analysis

MustGrow Biologics Corp (OTCQB: MGROF) has expanded its Canadian product portfolio through NexusBioAg with three new biological solutions. The new lineup includes:

EZ-Gro Max: A next-generation biostimulant with Bio-APP Technology, designed for multiple crops including Alfalfa, Barley, Canola, and others. It features a five-biostimulant stack to enhance foliar nutrition, plant growth, and yield potential while reducing environmental stress.

EZ-Gro Cyto: A four-biostimulant package that helps crops withstand drought, heat, cold, and salinity stress. It's optimized for various crops including Chickpeas, Lentils, and Sunflower.

Rootella®: Mycorrhizal inoculants developed by Groundwork BioAg® that enhance root networks, improve nutrient uptake, and offer fertilizer and water savings while supporting environmental sustainability.

MustGrow Biologics has signed a five-year exclusive distribution agreement with Adjuvants Plus Inc. on February 4, 2025, to distribute Adjuvants' product line across Canada through its NexusBioAg division. The agreement includes First Right of Refusal for U.S. market distribution.

The partnership focuses on four key products, particularly EndoFine® and EndoGuard®, which utilize patented Clonostachys rosea microbial technology for plant health and protection. These products target major crops including corn, soybean, pulses, canola, cereals, fruits, vegetables, and potatoes.

The products have been tested in NexusBioAg's BioAdvantage Trials Program, showing significant yield increases. With regulatory approvals in place, MustGrow plans to launch these products in Canada for the 2025 crop year and begin U.S. trials focusing on fruits & vegetables in California.

MustGrow Biologics Corp. (MGROF) has successfully closed a non-brokered private placement, raising $2,585,000 through the issuance of units priced at $1,000 each on January 16, 2025. Each unit consists of convertible debentures and 666 common share purchase warrants.

The debentures are convertible to common shares at $1.50 per share and carry an 8% annual interest rate, payable semi-annually. Warrants are exercisable at $1.90 per share for 60 months. The company paid $67,200 in finder's fees and issued 44,800 finder's warrants.

Company insiders participated by subscribing for 300 units ($300,000). Proceeds will be used for TerraSante™ inventory production, working capital, and general corporate purposes. All securities are subject to a four-month plus one-day hold period.

MustGrow Biologics Corp (TSXV: MGRO) (OTCQB: MGROF) has completed the acquisition of NexusBioAg from Univar Solutions Canada through an Asset Purchase Agreement dated December 31, 2024. The acquisition positions MustGrow as a fully integrated provider of biological and regenerative agriculture solutions with established sales, marketing, and distribution operations in Canada, with potential U.S. expansion opportunities.

The deal includes a deferred cash payment of approximately $1,662,000, subject to adjustments, and earn-out payments based on gross margin percentages from specific products sold in 2025 and 2026. The TSX Venture Exchange has granted conditional approval for the acquisition. The NexusBioAg division will market existing product lines, MustGrow's proprietary products, and potential third-party offerings, leveraging their experienced sales team and established industry relationships.

MustGrow Biologics (OTCQB: MGROF) has announced a proposed non-brokered private placement to raise approximately $2 million, with an option to increase by an additional $1 million. The placement consists of Units priced at $1,000 each, comprising convertible debentures and warrants. The debentures are convertible to common shares at $1.50 per share and carry an 8% annual interest rate. Each Unit includes 666 warrants exercisable at $1.90 per share.

The company plans to close the placement around January 10, 2025. Proceeds will be used for TerraSante™ inventory production, working capital, and general corporate purposes. The securities will have a four-month hold period and require TSX Venture Exchange approval.

MustGrow Biologics has signed a non-binding term sheet with Univar Solutions Canada to acquire NexusBioAg. The strategic acquisition, targeted to close by December 31, 2024, includes deferred cash payment and contingent payments in 2025 and 2026. The deal would position MustGrow as a fully integrated provider of biological and regenerative agriculture solutions in Canada. NexusBioAg's sales and marketing team would bring extensive experience and industry networks to drive growth. The integration would give MustGrow access to NexusBioAg's existing sales, with new third-party product lines planned for 2025 and MustGrow's proprietary TerraMG™ launching thereafter.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) has provided its 2024 pipeline update, marking a significant transition from R&D to commercialization. Key highlights include:

1. TerraSante™ biofertility product: Initial sales have commenced in key U.S. states, with potential for full-scale sales ramp-up in 2025 and 2026.

2. TerraMG™ soil biopesticide: Commercialization is progressing under the Bayer agreement for Europe, Middle East, and Africa. Registration work continues in the U.S. and Canada.

3. Intellectual property portfolio has grown to 112 issued and pending patents.

4. Expiration of exclusive non-commercial agreements with NexusBioAg, Janssen PMP, and Sumitomo

The company is focusing on delivering commercialization of its products, validating efficacy through sales, and driving global expansion.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) has secured funding from Agriculture and Agri-Food Canada (AAFC) to explore mustard-derived ingredient opportunities in human and animal health applications. The project, conducted at AAFC's Guelph Research & Development Centre, will investigate potential uses in:

• Functional foods and nutraceuticals for improved immunity and gut health
• Natural food preservatives
• Antibiotic replacements in animal feeds

The research aims to analyze bioactive components in mustard seed for antibiotic and gut health applications, assess their efficacy against food spoilage microbes and disease pathogens, and test their antioxidant and anti-inflammatory effects. This initiative aligns with global efforts to combat antimicrobial resistance, a significant threat to human and animal health.